KMT2A and leukemia: In this study, FZD was identified as a potential therapeutic candidate for acute myeloid leukemia (AML)., Therefore, we continued to test the efficacy of FZD on primary cells transformed by other leukemia fusion proteins including MLL-ENL, MLL-AF9, and R1A-RAR-RIIa [5], [6], [7], [8], [12] (Figure 1B, 1D).